Artemis partners with high profile Novo Resources


Published 29-MAY-2017 14:19 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Artemis Resources (ASX:ARV) announced on Monday morning that the company had negotiated a joint venture agreement with Novo Resources (TSX-V: NVO) with a view to fast tracking exploration of ARV’s Purdy’s Reward gold project and Novo’s adjacent Comet Well gold project which are located near Karratha in Western Australia.

Both of these projects feature gold bearing conglomerates over an extensive 8 kilometre strike with mineralisation characteristic of conglomerate/paleoplacer style gold mineralisation which is similar, or even a possible historic geological extension to the Witwatersrand gold province in South Africa.

Importantly, Novo brings experience in exploring and identifying such mineralisation. Furthermore, the company has prominent stakeholders with its largest shareholder being Newmont Mining Corporation. Other big names behind Novo are successful Western Australian prospector, Mark Creasy and renowned Canadian mining investor Eric Sprott.

With regard to Novo’s experience with this type of mineralisation, the company is currently moving its advanced gold bearing paleoplacer gold project at Beaton’s Creek near Nullagine towards production.

Novo released the news on Friday when its shares spiked 11% on the Toronto Stock Exchange (TSX).

It should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Novo to invest $2 million to earn into new 50/50 joint venture

The agreement will involve an immediate $2 million investment by Novo Resources to enter into a new 50/50 gold exploration, development, mining and collaboration joint venture. The agreement is specific to conglomerate gold play is only on ARV’s 1530 square kilometre tenements.

Exploration will commence immediately, and running parallel with this program will be an assessment by the joint venture regarding the prospects of using ARV’s radio Hill plant as a processing facility.

Commenting on other positive factors from a broader company perspective, ARV’s Chairman, David Lenigas said, “This agreement with Novo allows Artemis to keep its focus on developing our cobalt strategy at our Carlow Castle cobalt/copper/gold project and elsewhere, with further significant updates due to be released shortly.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free